SG Americas Securities LLC Decreases Stake in Novavax, Inc. (NASDAQ:NVAX)

SG Americas Securities LLC decreased its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 19.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 935,813 shares of the biopharmaceutical company's stock after selling 223,154 shares during the quarter. SG Americas Securities LLC owned about 0.58% of Novavax worth $5,999,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Novavax by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock valued at $126,439,000 after buying an additional 296,181 shares during the period. Sanofi purchased a new position in Novavax during the 4th quarter valued at $55,319,000. Geode Capital Management LLC boosted its holdings in Novavax by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock valued at $29,415,000 after acquiring an additional 155,206 shares during the period. Deep Track Capital LP purchased a new position in Novavax during the 4th quarter valued at $16,080,000. Finally, Northern Trust Corp boosted its stake in shares of Novavax by 6.1% during the fourth quarter. Northern Trust Corp now owns 1,451,715 shares of the biopharmaceutical company's stock valued at $11,672,000 after purchasing an additional 83,503 shares during the period. Hedge funds and other institutional investors own 53.04% of the company's stock.

Analysts Set New Price Targets

NVAX has been the subject of a number of recent analyst reports. B. Riley reissued a "buy" rating on shares of Novavax in a research note on Monday, May 19th. TD Cowen raised shares of Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research began coverage on Novavax in a report on Friday, February 28th. They issued a "buy" rating and a $19.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their price target on Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $19.20.

Novavax Trading Up 1.3%

Shares of NVAX traded up $0.09 during mid-day trading on Monday, hitting $7.03. The company's stock had a trading volume of 4,580,961 shares, compared to its average volume of 6,518,150. The company's 50-day moving average is $6.72 and its 200-day moving average is $7.69. Novavax, Inc. has a 52-week low of $5.01 and a 52-week high of $17.81. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -3.11, a PEG ratio of 2.85 and a beta of 2.80.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping analysts' consensus estimates of $0.71 by $2.22. The company had revenue of $666.66 million for the quarter, compared to analysts' expectations of $204.08 million. During the same quarter in the prior year, the company earned ($1.05) EPS. The firm's quarterly revenue was up 610.3% on a year-over-year basis. As a group, sell-side analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.